|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o ActoGeniX NV, of Ghent, Belgium, was awarded a C3.07 million (US$4.2 million) grant from the Flanders government through IWT (Institute for Promotion of Innovation by Science and Technology in Flanders). That funding, along with the C20 million the company raised in venture capital earlier this year, will support the discovery and development of programs based on TopAct, a platform for targeted delivery of biopharmaceuticals. The IWT funding, which covers a two-year period, will allow ActoGeniX to accelerate its application of TopAct to develop therapies in the areas of gastrointestinal, autoimmune, allergy and metabolic diseases. Its lead program has tested successfully ...